Thomas Mackie

Compact Particle Acceleration Corp. develops and commercializes compact intensity-modulated proton therapy systems. It systems are powered by the dielectric-wall accelerator (DWA), a revolutionary proton accelerator that will have a substantially smaller structure and greater flexibility than other accelerators. The firm’s proton therapy systems significantly reduce the amount of damage to adjacent healthy tissue that often occurs with traditional photon radiation methods. The company was founded in 2008 and is headquartered in Livermore, CA.

SHINE Technologies LLC manufactures radioisotopes for nuclear medicine. Its products include Molybdenum-99, Iodine-131, Iodine-125, and Xenon-133. The company was founded by Gregory R. Piefer and is headquartered in Monona, WI.

Geometrics Corp develops specialized medical computer systems. The company is based in Madison, WI. The company was founded by Mark A. Gehring, Thomas Rockwell Mackie. Geometrics was acquired by ADAC Laboratories, Inc. on November 04, 1996 for $3.90 million.

TomoTherapy, Inc. manufactures and provides radiation treatment systems for advanced radiation therapy. It provides radiation treatment services for cancer patients with its TomoTherapy Hi·Art System, which changes the intensity of the radiation beam so that it adapts to the shape of the tumor. The firm's system focuses on killing cancer cells while sparing healthy tissue. The company was founded by Thomas Rockwell Mackie and Paul J. Reckwerdt in 1997 and is headquartered in Madison, WI.

Novelos Therapeutics, Inc. is a pharmaceutical company, which is engaged in the development of novel drugs for the treatment and diagnosis of cancer. It comprises of three cancer-targeted compounds: GLOW2, HOT and LIGHT, which are used for the treatment of cancer. Its therapeutic compounds directly kill cancer cells while minimizing harm to normal cells. This offers the potential for a paradigm shift in cancer therapy by providing efficacy in all three major drivers of mortality in cancer: primary tumors, metastases and stem cell-based relapse. Its LIGHT compound is a small-molecule cancer-targeted imaging agent, which is potential for selective detection of tumors and metastases in a broad range of cancers. Its HOT compound is a small-molecule, broad-spectrum, cancer-targeted molecular radio therapeutic that delivers radiation directly and selectively to cancer cells and cancer stem cells. Its GLOW2 compound is a small-molecule, broad-spectrum, cancer-targeted, non-radioactive optical imaging agent which is potential for intraoperative tumor margin illumination and non-invasive tumor imaging. The company was founded on June 21, 1996 and is headquartered in Madison, WI.

Cellectar, Inc. is a clinical stage radiopharmaceutical company that designs and develops products to detect, treat and monitor a wide variety of human cancers. Cellectar began independent lab activities in February 2003 after forming a company and raising initial funds in the 2000-2002 timeframe. Its product candidates combine phospholipids ethers analogs (PLEs), which are lipid-like molecules, with radioisotopes that destroy or image malignant cancer cells. Because only malignant tumor cells and tissues retain large amounts of these compounds, malignant cancer-selective retention of therapeutic or diagnostic doses of radioactivity can be achieved. Cellectar has demonstrated specific uptake and retention of its product candidates in more than 45 tumor types tested in proof-of-principle preclinical animal studies. In addition, ten preclinical experiments have shown anti-tumor activity in each tumor type studied including breast, prostate, lung, glioma, pancreatic, melanoma, ovarian, uterine, renal and colorectal cancers. The compound, originally known as NM404, is being taken through the regulatory process as CLR1404. Capitalizing on the unique characteristics of malignant cancer cells, Cellectar's molecules will be designed to find, treat and follow malignancies through the delivery of radiopharmaceuticals in a novel, highly selective way.

BioIonix, Inc. supplies a breakthrough process equipment that solves advanced disinfection and oxidation problems. The firm's products are based on its proprietary and patented electrochemical processes along with its growing applications knowhow. The company was founded by James A. Tretheway and is headquartered in McFarland, WI.

The Morgridge Institute for Research, Inc. is a biosciences research institution. The private company is based in Madison, WI. The CEO of the company is Brad Schwartz.